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Abstract
Introduction: Tumor-initiating cells (TIC) are being extensively studied for their role in tumor etiology,
maintenance and resistance to treatment. The isolation of TICs has been limited by the scarcity of this population
in the tissue of origin and because the molecular signatures that characterize these cells are not well understood.
Herein, we describe the generation of TIC-like cell lines by ectopic expression of the OCT4 transcription factor (TF)
in primary breast cell preparations.
Methods: OCT4 cDNA was over-expressed in four different primary human mammary epithelial (HMEC) breast cell
preparations from reduction mammoplasty donors. OCT4-transduced breast cells (OTBCs) generated colonies
(frequency ~0.01%) in self-renewal conditions (feeder cultures in human embryonic stem cell media). Differentiation
assays, immunofluorescence, immunohistochemistry, and flow cytometry were performed to investigate the cell of
origin of OTBCs. Serial dilutions of OTBCs were injected in nude mice to address their tumorigenic capabilities.
Gene expression microarrays were performed in OTBCs, and the role of downstream targets of OCT4 in
maintaining self-renewal was investigated by knock-down experiments.
Results: OTBCs overcame senescence, overexpressed telomerase, and down-regulated p16INK4A. In differentiation
conditions, OTBCs generated populations of both myoepithelial and luminal cells at low frequency, suggesting that
the cell of origin of some OTBCs was a bi-potent stem cell. Injection of OTBCs in nude mice generated poorly
differentiated breast carcinomas with colonization capabilities. Gene expression microarrays of OTBC lines revealed
a gene signature that was over-represented in the claudin-low molecular subtype of breast cancer. Lastly, siRNA-
mediated knockdown of OCT4 or downstream embryonic targets of OCT4, such as NANOG and ZIC1, suppressed
the ability of OTBCs to self-renew.
Conclusions: Transduction of OCT4 in normal breast preparations led to the generation of cell lines possessing
tumor-initiating and colonization capabilities. These cells developed high-grade, poorly differentiated breast
carcinomas in nude mice. Genome-wide analysis of OTBCs outlined an embryonic TF circuitry that could be
operative in TICs, resulting in up-regulation of oncogenes and loss of tumor suppressive functions. These OTBCs
represent a patient-specific model system for the discovery of novel oncogenic targets in claudin-low tumors.
Introduction
Much evidence supports the hypothesis that tumor spe-
cimens and tumor cell lines are heterogeneous cell
populations comprising a hierarchical organization of
cell types [1-3]. Within this hierarchy, a rare population
of undifferentiated cells is able to self-renew, proliferate,
and develop into more differentiated tumor cells. The
population of tumor cells that retain the ability to self-
renew and generate tumors is commonly referred to as
tumor-initiating cells (TICs) or cancer stem cells [4].
The properties and molecular hallmarks of these cells
are not well understood, despite their pivotal role in
cancer etiology and resistance to treatment. In breast
cancer, prospective TICs have been isolated by flow
cytometry by using cell surface antigens, such as CD44
and CD24 [5]. However, the isolation of TICs has been
hampered because these cells represent a rare popula-
tion within the tumor, making it difficult to study their
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role in tumor biology. Thus, there is a need to develop
novel approaches for the isolation and molecular charac-
terization of TICs. These approaches ultimately will
facilitate the potential discovery of targeted therapeutics
that are specific for tumor cell initiation.
Recent advances in the field suggest that breast
tumors belonging to the claudin-low and basal-like
intrinsic subtypes are particularly enriched in TIC cell
signatures [6,7]. It has been proposed, on the basis of
genome-wide gene expression microarray studies, that
the more undifferentiated claudin-low and basal-like
tumors may originate from stem and early progenitor
cells, whereas luminal A and B tumors are possibly gen-
erated from more differentiated cell types [8,9]. Claudin-
low carcinomas are mostly triple-negative - negative for
progesterone receptor (PR), estrogen receptor (ER), and
epidermal growth factor receptor 2 (HER2) - and pre-
sumably originated from more primitive stem cells [10].
Hallmarks of these tumors include a high enrichment
for a CD44+/CD24-/low TIC signature, a downregulation
of cell junction proteins such as cadherins and claudins,
an enrichment in mesenchymal markers, high lympho-
cyte infiltrations, and high phenotypic resistance to che-
motherapy [6,11]. The relationship between breast stem
cells and gain of mesenchymal markers is further sup-
ported by a recent report that demonstrated that the
ectopic expression of transcription factors (TFs) known
to promote epithelial-to-mesenchymal transition (EMT)
resulted in the generation of breast cells with stem cell
properties [12].
Little is known regarding the factors maintaining self-
renewal gene programs and tumor initiation in claudin-
low and basal-like breast cancers. Evidence suggests that
networks of TFs play an essential role in activating self-
renewal gene programs, both in human embryonic stem
cells (hESCs) and in adult stem cells [13]. Furthermore,
some self-renewal TFs are found overexpressed in
poorly differentiated and high-grade tumors [13], sug-
gesting that some carcinomas could hijack underlying
self-renewal TF machinery to support aberrant prolifera-
tion and tumor initiation. Among these TFs, the OCT4
gene (also named POU5F1) encodes a homeodomain-
containing TF, which plays a pivotal role as master reg-
ulator or gatekeeper of self-renewal and pluripotency
[14]. Importantly, overexpression of OCT4 cDNA in a
mouse model led to the generation of dysplastic lesions
in epithelial tissues, such as the skin and colon, by aber-
rant expansion of early progenitor cells [15]. Recent
papers suggest that OCT4 is expressed in a subpopula-
tion of breast and ovarian cancer cells possessing self-
renewal ability [16,17]. Specifically, RNA interference
(RNAi)-mediated knockdown of OCT4 in tumor lines,
such as the breast MCF-7 line, and, most recently, in
poorly differentiated epithelial ovarian cancer cell lines
resulted in decreased survival [16] and inhibition of
tumorigenic potential [17]. Overall, these observations
point to an important role for OCT4 in maintaining
aberrant tumor cell self-renewal and, possibly, tumor
initiation in epithelial tissues.
In this paper, we have investigated the role of OCT4
as a potential driver of self-renewal in the human mam-
mary gland. Lentiviral delivery of OCT4 in primary
breast human epithelial cell preparations led to the iso-
lation of colonies (frequency of 0.01%) with infinite self-
renewal ability. These cells exhibited tumor-initiating
properties and metastasized in nude mice. Gene expres-
sion microarray analysis of OCT4-overexpressing cells
revealed a gene signature that was over-represented in
the claudin-low molecular subtype of breast cancer.
RNAi-mediated knockdown of OCT4 and embryonic
targets of OCT4 in these cells resulted in suppression of
the self-renewal ability, outlining the dependence of
OCT4 in the self-renewal phenotype. These results sug-
gest that OCT4-transduced breast colonies (OTBCs)
represent model cell lines to study self-renewal gene
programs dysregulated in poorly differentiated breast
tumors.
Materials and methods
Preparation of primary breast cells from fresh tissue
The first primary breast cell preparation was purchased
from a commercially available source (lot 7F3286, abbre-
viated mammoplasty p86; Lonza, Walkersville, MD,
USA). Subsequently, we generated three more primary
cultures (p48, p52, and p78) derived from normal breast
tissue procured from the Tissue Procurement Core
Facility of the University of North Carolina Lineberger
Comprehensive Cancer Center in accordance with
approved institutional review board (IRB) protocols
(Biomedical IRB, study 09-0777). Immediately after sur-
gery, tissues were collected in transport medium com-
posed of Dulbecco’s modified Eagle’s medium/F-12
(DMEM/F-12) and 10% fetal bovine serum (FBS) sup-
plemented with antibiotics (penicillin, streptomycin,
gentamycin, and amphotericin B). Next, the tissue was
gently minced after removal of stromal matrix and fatty
areas. The epithelial-containing tissue was enzymatically
dissociated by using digestion medium containing the
following reagents: Ham’s F-12/DMEM (1:1) supplemen-
ted with 10% FBS, 5 g/mL insulin (Sigma-Aldrich, St.
Louis, MO, USA), 0.5 g/mL hydrocortisone (StemCell
Tech, Vancouver, BC, Canada), 10 ng/mL cholera toxin
(Sigma-Aldrich), collagenase/hyaluronidase 10× (Stem-
Cell Tech), and antibiotics. For complete digestion, the
samples were placed at 37°C for 16 to 18 hours with
gentle rotation. Breast organoids were separated by dif-
ferential centrifugation at 80 g for 30 seconds. The
epithelial fraction was obtained by centrifugation at 160
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g for 2 minutes. For transduction experiments, cells
were used at first or second passage.
Cell lines
Immortalized human dermal fibroblasts and the human
neural teratoma cell line NT2 (American Type Culture
Collection, Manassas, VA, USA) were grown in DMEM
supplemented with 10% FBS and antibiotics. Breast cell
preparations (parental lines) were grown in mammary
epithelial basal media (MEBM) (Lonza) supplemented
with bovine pituitary extract, hydrocortisone, insulin,
human epithelial growth factor (hEGF), and antibiotics.
OTBCs were grown in mammosphere medium, MEBM
(Lonza) containing 1 ng/mL hEGF (BD Biosciences, San
Diego, CA, USA), 1 μg/mL hydrocortisone (StemCell
Tech), 10 μg/mL insulin (Sigma-Aldrich), 4 ng/mL
heparin (StemCell Tech), B27 (Invitrogen Corporation,
Carlsbad, CA, USA), and antibiotics. All cells were
grown in 5% CO2 at 37°C in a humidified incubator.
Lentivirus preparation and transduction of primary breast
cells
Lentiviral particles were prepared from HEK 293T
packaging cells. Briefly, plasmids containing pSinOCT4
(Addgene, Cambridge, MA, USA), Gagpol, VSVG, and
RSV-REV were transfected in HEK 293T cells by using
Lipofectamine and Plus Reagent cationic lipids (Invitro-
gen Corporation). An empty lentiviral vector was used
as a negative control. Culture media containing viral
particles were collected 36 hours after transfection and
filtered through a 22-m filter. Virus was concentrated by
ultra-centrifugation at 2.8 × 104 revolutions per minute
for 2 hours at 4°C. Virus was resuspended in MEBM
plus bullet kit culture media (Lonza) supplemented with
8 g/mL polybrene (Sigma-Aldrich). Primary breast cells
were seeded 24 hours prior to transduction in 100-mm
dishes at 1 × 105 cells per plate. To maximize transduc-
tion efficiency, primary breast cells were transduced
four times in 48 hours.
Derivation of OCT4-transduced breast cells
Inactivated mouse embryonic fibroblasts (MEFs)
(C57BL/6; IRR #SCRC-1008; American Type Culture
Collection) were seeded on 0.1% gelatin-coated six-well
plates at a density of 1.5 × 104 cells/cm2. Immediately
after the fourth transduction, breast cells were trypsi-
nized and seeded on MEF-coated plates in hESC media
[18]. Typically, control-transduced and non-transduced
cells formed transient colonies that lasted 3 weeks. The
OTBCs were highly proliferative and mesenchymal-
appearing. OTBCs were picked between 21 and 28 days
after seeding on MEFs and transferred to secondary and
tertiary feeder cultures. After the third passage, colonies
were mechanically dissociated and transferred to low-
attachment plates (Corning, Corning, NY, USA) and
mammosphere medium. OTBCs were maintained in
self-renewal conditions as spheroids and were passaged
every 5 days.
Senescence assays
For b-galactosidase senescence assays, 5 × 104 OTBCs
and parental lines were seeded in a six-well plate. Stain-
ing was done with the senescence b-galactosidase stain-
ing kit in accordance with the instructions of the
manufacturer (Cell Signaling Technology, Inc., Danvers,
MA, USA), b-galactosidase-positive cells from parental
and OTBC lines were counted, and the average of four
different fields was plotted.
Quantitative real-time polymerase chain reaction
Total RNA from all cell lines was extracted by using the
RNeasy extraction kit (Qiagen, Valencia, CA, USA) in
accordance with the instructions of the manufacturer.
Five grams of total RNA was reverse-transcribed by
using the high-capacity cDNA archive kit (Applied Bio-
systems, now known as Life Technologies, Carlsbad,
CA, USA) plus RNase inhibitor (Applied Biosystems).
Gene transcription was quantified by qRT-PCR by using
hydrolytic probes (Taqman; Applied Biosystems) or
Absolute Blue QPCR SYBR low Rox mix (Thermo
Scientific, Rockford, IL, USA). Fold change in gene
expression for each sample and experimental condition
was calculated as 2Ct(control) - Ct(sample) ± standard devia-
tion. Primers and probes are listed in Table S1 in Addi-
tional file 1.
Differentiation culture conditions
Cells were resuspended in 20 μL of Matrigel™ (BD
Biosciences, San Diego, CA, USA). The Matrigel™ cell
mixture was placed at the bottom of the well (eight-well
Lab-Tek; Thermo Scientific, Rochester, NY, USA) and
allowed to sit at 37°C for 30 minutes. The well was filled
with 300 μL of differentiation medium: Ham’s F-12
medium with 5% FBS, 5 μg/mL insulin (Sigma-Aldrich),
1 μg/mL hydrocortisone (StemCell Tech), 10 μg/mL
cholera toxin (Sigma-Aldrich), 10 ng/mL epithelial
growth factor (BD Biosciences), and 1 μg/mL prolactin
(Sigma-Aldrich). Cells were cultured for 3 weeks in 5%
CO2. Cells were fed with medium every other day. Cells
were fixed with 4% paraformaldehyde and permeabilized
with 0.3% triton-X100 before being processed for immu-
nostaining [19].
Differentiating culture for terminal ductal lobular unit
assay
Cells were grown in three-dimensional (3D) basement
membrane culture. Growth factor-reduced Matrigel™
(BD Biosciences) was combined in a 1:1 ratio with
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differentiation medium; 100 μL was added to each well
of an eight-well glass slide chamber (Lab-Tek; Thermo
Scientific) and allowed to solidify for 2 hours in a 37°C
incubator. Cells were trypsinized, counted, and diluted
to 500 cells per well. A 30% Matrigel™ solution was
prepared in differentiation medium. The cell suspension
was combined in a 1:1 ratio with the 30% Matrigel™
solution, and 200 μL of this mixture was added to each
well. Prolactin was added to the media at a concentra-
tion of 1 μg/mL for the alveolar differentiation assays
only. Cells were fed with differentiation medium con-
taining 5% Matrigel™ every 4 days.
Short interfering RNA target gene knockdown
OTBCs were reverse-transfected with 50 nM short
interfering RNA (siRNA) smart pools (4 siRNAs per
pool; Thermo Fisher Scientific, Lafayette, CO, USA),
complexed with dharmaFECT reagent (Thermo Fisher
Scientific). Transfection conditions were optimized by
using a cytotoxic siRNA targeted against human ubiqui-
tin B (Thermo Fisher Scientific). Spheroids or mammo-
spheres from single cells were allowed to form in
mammosphere medium as described above. For knock-
down validation, cells were transfected in low-adherence
six-well plates at 2.5 × 105 cells per well. Cells were left
in transfection media for 48 hours for cell viability
assays and 72 to 96 hours for Western blot analysis of
target gene knockdown.
Cell viability assays
Cells were reverse-transfected with siRNAs in 96-well
low-adherence plates at 5 × 103 cells per well with four
replicates. The Cell Titer Glo (CTG) assay (Promega
Corporation, Madison, WI, USA) was used to determine
the number of viable cells in low-adherence plates
(mammosphere conditions) after siRNA transfection.
Plates were allowed to cool down to room temperature,
and 10 μL of CTG reagent was added per well and incu-
bated for 15 minutes on an orbital shaker. Plates were
assayed for luminescence in a plate reader (Pherastar,
Ortenberg, Germany).
Mouse tumor studies
Female athymic nude mice (3 weeks old) were pur-
chased from Harlan Laboratories } (San Diego, CA,
USA) for fat pad xenografts. The Institutional Animal
Care and Use Committee at the University of North
Carolina at Chapel Hill approved all of the following
described experiments (protocol 08-311.0). Female
nude/severe combined immunodeficient (nude/SCID)
mice (3 weeks old) were purchased from Taconic Farms
(Hudson, NY, USA) for subcutaneous xenografts and
the spontaneous metastasis assays. Fat pad xenografts
were generated with 1 × 105 OTBCs and a mixture of
irradiated and non-irradiated immortalized fibroblasts
(1:1, 1 × 105 cells total) in a final volume of 50 μL. The
inguinal fat pad number four of 3-week-old mice was
cleared and injected with the cell mix. Estrogen pellets
were implanted subcutaneously at the time of the injec-
tion. All animals were euthanized when the tumors
were approximately 1.2 cm in the largest length.
Tumors were collected and processed for histology and
inmmunohistochemistry. Subcutaneous xenografts were
generated by injecting animals in the flank with 1 × 106
OTBCs diluted with Matrigel™ (1:1). Fluorescence ima-
ging was performed with a highly sensitive cooled CCD
(charge-coupled device) camera mounted in a light-tight
specimen box (IVIS™; Xenogen, Taconic Farms (Hud-
son, NY, USA)). Signal quantification was obtained by
Living Image (Xenogen, Taconic Farms (Hudson, NY,
USA)) software. For in vivo imaging, animals were
anesthetized (1% to 3% isoflurane) and imaged from
dorsal and ventral sides once a week. Spontaneous
metastases were evaluated by injecting four female
nude/SCID mice (3 weeks old) with 1 × 105 OTBCs-86-
L1-Ds-Red cells in 50 μL of sterile PBS in the left ven-
tricle of the heart. Imaging of the metastatic lesions was
performed in vivo once a week. For TIC experiments,
animals were injected in the flank with OTBCs-86-L1-
Ds-Red cells diluted to 1, 50, 1, 000, 100, 000, and 1,
000, 000 cells in a 100 μL PBS/Matrigel™ (1:1) mixture.
Tumor growth was monitored by caliper measurement
and fluorescence imaging as described above.
Gene expression microarrays
A total of 11 cell lines were used for gene expression
analyses: 4 parental cell lines (p48, p52, p78, and p86), 6
OTBCs (OTBCs48-L1, OTBCs52-L1, OTBCs78-L1,
OTBCs86-L6, OTBCs86-L4, and OTBCs86-L1), and 1
OCT4 siRNA cell line (with 1 technical replicate). In
addition, one tumor sample generated from the
OTBCs86-L1 cell line was used for gene expression ana-
lysis. From each sample, total RNA was purified, ampli-
fied, labeled, and hybridized by using Agilent (Agilent
Technologies, Santa Clara, CA, USA) 4 × 44 K oligo
microarrays (platform GPL7504). All microarray data
have been deposited in the Gene Expression Omnibus
under accession number GEO:GSE26539. The probes/
genes were filtered by requiring the lowest normalized
intensity values to be greater than 10 in both samples
and controls. The normalized log2 ratios (Cy5 sample/
Cy3 control) of probes mapping to the same gene were
averaged to generate independent expression estimates.
We also used available microarrays from the UNC337
dataset [6]. For the UNC337 dataset, genes were med-
ian-centered, and samples were standardized to zero
mean and unit variance before other analyses were per-
formed. All microarray cluster analyses were displayed
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by using Java Treeview version 1.1.3. Average-linkage
hierarchical clustering was performed by using Cluster
version 2.12 [20]. Analysis-of-variance tests for gene
expression data were performed using R.
OCT4-transduced breast cell gene signatures
To build an OTBC signature, we first selected those
genes that were significantly and differentially expressed
between six OTBCs (OTBCs48-L1, OTBCs52-L1,
OTBCs78-L1, OTBCs86-L6, OTBCs86-L4, and
OTBCs86-L1) and their four respective parental cell
lines (p48, p52, p78, and p86) by using two-class paired
SAMs (significance analysis of microarrays) and a less
than 1% false-discovery rate. The resulting upregulated
(n = 534) and downregulated (n = 1, 144) gene lists are
shown in supplemental data (Tables S4 and S5, respec-
tively). To estimate the expression of the OTBC signa-
ture across the intrinsic molecular subtypes of breast
cancer, we calculated the mean expression of both gene
lists (that is, up- and downregulated) in the entire med-
ian-centered UNC337 dataset (n = 327) by using the
subtype calls described in [6]. Among the entire gene
list of the OTBC signature (n = 1, 678), only three
genes were found missing in the UNC337 dataset.
Immunofluorescence, flow cytometry, Western blot-
ting, immunohistochemistry, and small-molecule epige-
netic inhibitor treatments are described in
supplementary methods in Additional file 2. Primary
and secondary antibodies were used in accordance with
the recommendations of the manufacturer and are listed
in Table S2 in Additional file 3.
Results
Isolation of OCT4-overexpressing clones from normal
breast preparations with persistent self-renewal ability
To isolate clonal populations of OCT4-overexpressing
cells with sustained self-renewal ability, approximately 1
× 105 human mammary epithelial cells were lentivirally
transduced and seeded in feeder cultures of irradiated
fibroblasts in hESC media, conditions known to facilitate
the expansion of adult and embryonic stem cells (Figure
1). Control and mock-infected cells generated transient
colonies that survived approximately 2 to 3 weeks. How-
ever, OCT4 cDNA transduction produced 1 to 10 colo-
nies per 1 × 105 transduced cells. In contrast to control
colonies, these OCT4-transduced breast colonies (abbre-
viated as OTBCs) were visible 2 weeks after seeding in
MEF conditions (Figure 1). OTBCs appeared non-encap-
sulated in feeder cultures and exhibited a distinctive
transparent mesenchymal-like morphology with multiple
visible secretion vesicles. These colonies could be propa-
gated in secondary feeder cultures and thus sustained
self-renewal ability. We recovered a total of six OTBCs
from the commercially available source (mammoplasty
p86), two colonies from p48, two colonies from p52,
and five colonies from p78. In all cases, no colonies
were recovered in control cells (un-transduced cells or
cells transduced with an empty vector). To maintain the
OTBCs in self-renewal conditions in feeder-free cul-
tures, colonies from secondary passages of feeder cul-
tures were then propagated in mammosphere media in
low non-adherent plates, which are culture conditions
known to expand mammary stem and progenitor cells
[8]. Because of technical limitations in obtaining a suffi-
cient number of cells for biological assays, we chose the
six OTBCs derived from p86 and one line derived from
p48 for future studies. These seven lines displayed the
highest proliferation rates among all the clones analyzed.
Unlike the parental primary breast preparations used for
the transductions, which could not be further propa-
gated for more than three to seven serial passages in
spheroid conditions (mammospheres), these OTBCs
could be propagated for more than 40 passages. Impor-
tantly, identical mesenchymal colonies could be isolated
when the transduced cells were seeded in feeder-free
conditions (cells grown in gelatin-coated plates in MEF-
conditioned media), indicating that the isolated OTBCs
were not a contamination from the feeder cultures.
Overall, these observations suggested that a rare popula-
tion of epithelial cells (up to 0.01% of mammary epithe-
lial cells) could be immortalized and infinitely
propagated in self-renewal spheroids by expression of
OCT4 cDNA.
OCT4-transduced breast cells defeat the cellular
senescence process
We first measured b-galactosidase activity, which is a
marker of cellular senescence, in both the parental lines
and their derived OTBCs. Most of the cells in the par-
ental lines at passage seven stained strongly positive for
b-galactosidase, whereas only a few cells in the OTBCs
were positive in the same assay, suggesting that OTBCs
bypassed the cellular senescence process (Figure 2a).
Both shortening of telomeres and proteins regulating
cell cycle, such as p16INK4A, are known to play an
important role in cell aging [21,22]. The maintenance of
telomere ends by the telomerase reverse transcriptase
(hTERT) and the downregulation of regulator p16INK4A
are two of the mechanisms for the self-renewal of stem
cells [23]. Therefore, we next examined hTERT and
p16INK4A mRNA levels by qRT-PCR in OTBCs and par-
ental lines. As shown in Figure 2b, OTBCs upregulated
hTERT mRNA levels by more than 1, 000-fold relative
to the parental lines. The hTERT levels in OTBCs were
similar to those of the SUM159PT breast cancer cell
line [1]. In contrast to hTERT levels, p16INK4A mRNA
levels were completely downregulated in OTBCs when
compared with their respective parental lines (Figure
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Figure 1 Generation of OCT4-transduced breast cells (OTBCs) from primary cultures of mammary cells. Graphical representation of the
method used to generate OTBCs from normal breast tissue. Representative images of control cells (empty lentiviral vector) and OTBCs are
shown 2 weeks after transduction of OCT4 and seeding in feeder cultures of mouse embryonic fibroblasts in human embryonic stem cell (hESC)
media. The OTBCs-86L1 image is a representative example of cells (passage 25) grown in suspension in mammosphere media after cell
expansion.
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2c). These results indicated that OTBCs overcame cellu-
lar senescence and underwent an immortalization
process.
OCT4-transduced breast cells maintain aberrant self-
renewal and are able differentiate into breast epithelial
cell lineages
We next examined the phenotypic properties of the cell of
origin of OTBCs by performing differentiation assays.
When single-cell suspensions of OTBCs were placed in
3D cultures of Matrigel™ and prolactin, terminal ductal
lobular-like units (TDLUs) were formed with primary, sec-
ondary, and tertiary branching structures (Figure 3a).
These TDLU-like structures were very similar morpholo-
gically to those reported for bi-potent stem cells and can-
cer stem cell lines [24]. The formation of these structures
suggested that the cell of origin that gave rise to OTBCs
was possibly a primitive stem cell or early progenitor cell.
To verify this, we assessed the differentiation potential of
OTBCs by seeding single-cell suspensions of OTBCs in
fibronectin-coated wells for 4 days. Lineage specification
was followed by immunofluorescence by using specific
antibodies. As shown in Figure 3b, all OTBCs analyzed
were able to generate myoepithelial-specific (CK14+, SMA
+, and Maspin+) cell populations. However, only a popula-
tion of cells within the colony (usually appearing as
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Figure 2 OCT4-transduced breast cells (OTBCs) underwent an immortalization process. (a) OTBCs overcame cellular senescence. The
histogram quantifies b-galactosidase-positive cells in the OTBCs-86L1 and OTBCs-48L1 lines. Data were normalized to the parental cell lines p86
and p48 and represent the mean ± standard deviation (SD) of three independent experiments (*P ≤0.01). (b) Telomerase mRNA levels are
upregulated in OTBCs relative to the parental p86 and p48 lines. The SUM159PT breast cancer cell line was used as a positive telomerase gene
expression control. Samples were normalized to the parental p86 and p48 lines. Bar graphs represent the mean ± SD of three independent
experiments. (c) OTBCs downregulate p16Ink4a mRNA levels as assessed by quantitative real-time polymerase chain reaction. The p16Ink4a levels in
OTBCs were normalized to the parental lines. Bar graphs represent the mean ± SD of three independent experiments. hTERT, human telomerase
reverse transcriptase.
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clusters of cells possibly arising from a single cell) was able
to differentiate, and most cells still maintained strong
OCT4 nuclear staining. In addition to myoepithelial-posi-
tive cells, some OTBCs generated luminal-specific cell
populations, such as cytokeratin (CK) 19+ cells and epithe-
lial cell adhesion molecule-positive (EpCAM+) cells (Fig-
ure S1 in Additional file 4). CK14+ and CK19+ colonies
were detected when OTBCs were allowed to differentiate
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in Matrigel™ (Figure 3a, right panel). The fact that only a
relatively small population of cells was able to differentiate
and that OCT4 was still highly expressed in OTBCs sug-
gested that these cells maintained aberrant self-renewal
and were limited from undergoing downstream differen-
tiation gene programs. We concluded, on the basis of
these differentiation assays in vitro, that OCT4 trans-
formed a stem or early progenitor cell. Some OTBCs (for
example, OTBCs86-L1) were bi-potent cells, able to gener-
ate both lineages, whereas other OTBCs (for example,
OTBCs78-L1) appeared to be myoepithelial-restricted.
Nevertheless, the fact that all OTBCs were able to give rise
to CK+ cells was consistent with an epithelial origin and
excluded the possibility that these cells were generated
from minor stromal contaminants present in the epithelial
preparations.
Stem and tumor-initiating cell-like antigenic properties of
OCT4-transduced breast cells in vitro
We first investigated the antigenic signatures of OTBCs
and their parental lines by flow cytometry by using cell
surface marker panels used to identify prospective breast
stem and progenitor cells. As shown in Figure 3c and in
Figure S2 in Additional file 5, all OTBCs were EpCAM-,
CD49f+, and CD133low. These markers are consistent with
reported signatures characterizing putative stem/progeni-
tor cells of the breast [8]. Levels of CD49f were more vari-
able among OTBCs, but all clones consistently stained
positive for this marker (Figure S2 in Additional file 5).
The finding that all OTBCs were EpCAM- suggest that
the cell of origin of OTBCs is possibly not a luminal-
restricted progenitor but rather a breast stem cell, a bi-
potent progenitor, or a myoepithelial-restricted progenitor
cell, and this is in agreement with the results of our differ-
entiation assays. Next, we examined the prevalence of the
CD44high/CD24- signature, which has been used to isolate
prospective breast TIC populations in tumor specimens
and cell lines [2,5]. As shown in Figure 3c and in Figure
S2 in Additional file 5, all of the OTBCs analyzed acquired
the tumorigenic, TIC-like signature, CD44high/CD24-.
Tumorigenic capabilities of OCT4-transduced breast cells
in immunodeficient mice
The aberrant self-renewal ability of OTBCs and the pre-
valence of the CD44high/CD24- TIC signature in all of
the OTBCs suggested that these cell lines could have
tumorigenic potential in vivo. High CD44high/CD24-
ratios have been associated with the claudin-low breast
cancer subtype [6,11]. To explore the potential of
OTBCs to generate tumors, we first developed orthoto-
pic models. Cells (1 × 105) from OTBCs86-L1 were
injected in the fat pad of nude mice in the presence of
human fibroblasts (Table S3 in Additional file 6), which
are commonly used to support the growth of mammary
stem cells and other TIC lines [25]. We additionally
injected 1 × 105 cells from OTBCs86-L1 in the absence
of fibroblasts with Matrigel™ in the flank of nude mice
(Table S3 in Additional file 6). We found that the fat
pad injection in the presence of stromal fibroblasts
highly facilitated the growth of these cells and that all of
the animals developed fast-growing tumors in less than
2 weeks after injection. The same cells injected subcuta-
neously in the absence of fibroblasts developed tumors
at day 16 after injection. We next performed a cell dilu-
tion experiment to address whether OTBCs acquired
tumor-initiating potential. As shown in Table 1, 50 cells
from OTBC-86-L1 were sufficient to generate subcuta-
neous tumors in five out of eight injected animals.
Thus, these results indicated that OTBCs acquired
tumor-initiating capabilities.
To image these tumors in vivo, non-invasive fluores-
cence imaging was performed by using OTBC-86-L1
cells expressing DsRed (Figure 4a, i). Immunohistologi-
cal examination of these primary tumors revealed histo-
logical features reminiscent of high-grade, poorly
differentiated breast carcinomas. The majority of pri-
mary tumor cells retained high OCT4 nuclear expres-
sion (Figure 4b) and comprised high-grade atypical cells
with high nuclear-to-cytoplasmic ratio, prominent
nucleoli and a high mitotic index, the last of which is
another hallmark of poorly differentiated human breast
cancers [13] (Figure 4c, d). The vast majority of subcu-
taneous and orthotopic tumors were strongly positive
for the mesenchymal marker vimentin (VIM) (Figure
4e). Pathological examination of the tumors suggested
that OTBCs generated poorly differentiated epithelial
breast carcinomas, which were negative for PR, ER, and
HER2. Importantly, a subset of tumor cells stained posi-
tive for CKs, such as CK19 (Figure 4g), CK8/CK18 (Fig-
ure 4h), and pan-keratin (AE1/AE3) (Figure 4f). In
Table 1 Tumor-initiating cell capabilities of OTBCs86-L1
Cell line Number of cells injected subcutaneously Number of tumors Days
OTBCs86-L1-DsRed 1, 000, 000 9/9 9
100, 000 6/6 16
1, 000 8/8 25
50 5/8 45
1 0 > 90
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conclusion, analysis of tumor pathology supports the
classification of these tumors as carcinoma of epithelial
origin.
To determine the metastatic potential of OTBCs,
OTBC-86-L1-DsRed cells were injected in the left heart
ventricle of nude mice (Table S3 in Additional file 6).
The red fluorescent protein allowed the detection of
metastatic lesions by using a Xenogen fluorescence-ima-
ging camera in living animals (Figure 4i) and in tumor
sections (Figure 4n). Metastases were evident in two out
of four animals 2 months after injection, with multiple
lesions, including ovarian metastases (Figure 4i-p). The
immunohistochemical analysis of the metastases
revealed poorly differentiated high-grade tumor cells
(Figure 4k, l) and strong OCT4 staining in most of the
cells (Figure 4o) and weak positive staining for VIM
(Figure 4m), and this was similar to what was observed
in primary tumors.
Overall, these in vivo assays demonstrated that OTBCs
were able to generate subcutaneous and orthotopic
tumors that were reminiscent of high-grade, triple-nega-
tive, and poorly differentiated breast carcinomas. Similar
tumors were obtained with independent injection of
three additional OTBC clones (see Table S3 in Addi-
tional file 6 for all mouse experiments). Collectively, our
data show that the OTBC lines acquired TIC properties.
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Figure 4 OCT4-transduced breast cells (OTBCs) generate primary tumors and experimental metastases upon injection in
immunodeficient mice. (a) Representative image of a prototype subcutaneous primary tumor generated by OTBCs86-L1-DsRed cells. Control
mice were injected with the parental p86 line. Animals were injected with 1 × 106 cells; for simplicity, only one animal is shown. The OTBCs86-
L1-DsRed was engineered with a lentiviral vector expressing the DsRed gene, which facilitated tumor measurement by fluorescence imaging
(IVIS-kinetic; Xenogen). Shown is a representative paraffin-embedded tumor section stained with (b) OCT4 (40×), (c) hematoxylin and eosin (H&E)
(40×), (d) H&E magnification from (c), (e) vimentin (VIM) (20×), (f) pan-keratin (AE1/AE3, 20×), (g) keratin 19 (20×), and (h) keratin 8/18 (20×). (i)
Representative image of spontaneous metastatic lesions. Immunodeficient mice were injected in the left ventricle of the heart with OTBCs86-L1-
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expressing OCT4.
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OCT4-transduced breast cells exhibit a loss of epithelial
and gain of mesenchymal markers
To gain mechanistic insight into how OTBCs developed
aberrant self-renewal and gain of TIC features, we inves-
tigated the molecular targets of OCT4. We performed
gene expression microarray analysis on four parental
normal breast preparations (designed as p52, p78, p86,
and p48 in Figure 5a) and their corresponding OTBC-
derived lines (three OTBC lines derived from p86 and
one line from each of the remaining parental lines). The
genome-wide transcriptional analysis revealed that all
OTBCs maintained a poorly differentiated state as
reflected by the weak expression of epithelial markers
(CKs 5, 14, 17, 18, and 19), loss of TFs specifying line-
age commitment such as GATA3, and the concomitant
gain of self-renewal TFs, such as OCT4 and NANOG.
Furthermore, all OTBC lines examined exhibited a com-
plete loss of epithelial junction markers, such as E-cad-
herin and members of the claudin gene family, and a
gain of mesenchymal markers, such as VIM.
Figure 5 OCT4-transduced breast cells (OTBCs) exhibit an epithelial-to-mesenchymal transition (EMT) gene signature. (a) Microarray
expression analysis of genes selected across parental (p48 and p86), OTBC lines (OTBCs48-L1 and L2, OTBCs86-L1, L4, and L6), and a
subcutaneous tumor derived from OTBCs86-L1 (tumor 86-L1). Array trees were derived by unsupervised hierarchical clustering using markers of
EMT, basal, luminal stem cell, cancer stem cell, and epithelial differentiation. Each colored square on the upper right represents the relative mean
transcript abundance (in log2 space); highest expression is red, average expression is black, and lowest expression is green. (b) Western blot
detection of molecular markers in the parental lines (p86 and p48), OTBCs86-L1 through L6, and OTBCs48-L1. The following markers were
analyzed: OCT4, NESTIN, CDH1, Maspin, vimentin, and N-CAM. Tubulin was used as a loading control. Results are representative examples of
three independent experiments. (c) Detection of EMT transcription factor expression by quantitative real-time polymerase chain reaction (qRT-
PCR). Gene expression levels were normalized to those of the parental cell lines (p86 and p48). Control cell lines used for gene expression
analyses include human dermal fibroblasts and the human teratoma cell line NT2. (d) MicroRNAs (miRNAs) known to promote epithelial
differentiation are detected by qRT-PCR. Levels of miRNA expression in OTBCs of miR-141, miR-200a, miR-200b, miR-200c, and miR-205 were
normalized to those of the parental lines (p86 and p48). Analysis was performed by using miR-U6 as an internal control. Bar graphs represent
the mean ± standard deviation of three independent experiments. CDH1, E-cadherin; N-CAM, neural cell adhesion molecule.
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Interestingly, a sample derived from a subcutaneous
tumor injected with OTBCsp86-L1 (tumor 86-L1) (Fig-
ure 5a) revealed a small reactivation of CKs relative to
the original OTBC line used to generate the tumor.
This finding supports the histological data of Figure 4,
suggesting that possibly only a fraction of cells within
the tumors are able to differentiate in CK+ cells.
The gain of stem cell markers and loss of epithelial
proteins were also validated by Western blot analysis
and qRT-PCR (Figure 5b, c). OTBCs retained high
expression of the stem cell marker Nestin, which has
been shown to be overexpressed in isolated mammary
stem cells [8,26] (Figure 5b). All OTBCs exhibited a
complete loss of epithelial markers associated with
tumor suppressive functions, such as E-cadherin
(CDH1) and Maspin, and a gain of mesenchymal mar-
kers, such as VIM and neural cell adhesion molecule
(N-CAM). N-CAM is essential for EMT induction [27]
and for the maintenance of a mesenchymal state [28].
Other TFs known to facilitate EMT, such as TWIST,
SNAIL1, SNAIL2, ZEB1, and ZEB2, were upregulated in
OTBCs (Figure 5c). Furthermore, microRNAs that pro-
mote epithelial differentiation by targeting the EMT TFs
ZEB1/2 (members of the miR-200 family [29,30] and
miR-205 [31]) were all downregulated in OTBCs (Figure
5d). Overall, these results demonstrate that OTBCs
maintained stem cell/progenitor characteristics and
gained mesenchymal markers relative to their parental
lines.
OCT4-transduced breast cells resemble the claudin-low
molecular subtype of breast cancer
A hallmark of the claudin-low subtype of breast cancer
is the enrichment of mesenchymal markers along with
the downregulation of epithelial junction proteins,
including E-cadherin and claudins [6]. Indeed, EMT has
been associated with stemness and mammary gland
tumorigenesis [12]. We next examined overlapping gene
signatures between OTBCs and claudin-low carcinomas.
OTBCs from four different mammoplasty donors
revealed very similar genome-wide transcriptional pro-
files, which facilitated the generation of two robust sig-
natures of genes significantly up- and downregulated,
respectively, in all OTBCs samples relative to their par-
ental lines. These upregulated (n = 534) and downregu-
lated (n = 1, 144) gene signatures were examined across
the intrinsic molecular subtypes of breast cancers by
using a published cohort of 337 samples [6]. Our analy-
sis shows that the up- and downregulated gene signa-
tures were significantly over-represented or under-
represented in the claudin-low subtype, respectively
(Figure 6; Tables S4 and S5 in Additional files 7 and 8).
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Figure 6 OCT4-transduced breast cells (OTBCs) up- and downregulate genes clustered with the claudin-low molecular subtype of
breast cancer. Box-and-whisker plot for the mean expression of the upregulated (534 genes) and downregulated (1, 144 genes) gene
signatures (Tables S4 and S5 in Additional files 7 and 8, respectively) in OTBCs compared with the parental cell lines across the intrinsic
molecular subtypes of breast cancer by using the published breast cancer patient database (UNC337) [6]. P values have been calculated by
comparing gene expression means across all subtypes. HER2, epidermal growth factor receptor 2.
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Thus, our genome-wide analysis supported the finding
that OCT4 overexpression in OTBCs strongly correlated
with a subset of breast carcinomas enriched in cancer
stem cell gene signatures and mesenchymal markers.
Activation of targets of NANOG, OCT4, and SOX2 in
OCT4-transduced breast cells
To investigate the molecular mechanisms mediating the
tumor-initiating capabilities of OTBCs, we examined the
expression of OCT4 and its downstream targets by gene
expression microarrays and qRT-PCR. In hESCs, OCT4,
SOX2, and NANOG TFs comprise the core of an auto-
regulatory feedback loop that activates self-renewal and
inhibits differentiation gene programs [32]. Common
targets of NANOG, OCT4, and SOX2 have been charac-
terized by ChIP-chip and ChIP-seq in hESCs and mouse
ESCs [32,33]. In hESCs, these TFs co-occupy and co-
regulate a subset of 179 targets (known as the NANOG,
OCT4, and SOX2 (NOS) signature [13]). Our gene
expression microarrays revealed that multiple hESC
NOS targets were differentially regulated in the OTBCs
relative to the parental lines (Figure 7a). Furthermore,
the expression of these targets was significantly per-
turbed in OTBCs depleted of OCT4 by RNAi-mediated
knockdown (Figure 7a). These results suggested that
OTBCs regulated direct embryonic targets of OCT4.
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Figure 7 Differential regulation of the human embryonic targets of NANOG, OCT4, and SOX2 (NOS targets) in OCT4-transduced breast
cells (OTBCs). (a) Expression of selected NOS targets across the parental cell line p86, the OTBCs86-L1 cell line, and the same line OTBCs86-L1
transfected with a short interfering RNA specific for OCT4. Efficient knockdown of OCT4 was validated by Western blot. Each colored square on
the left panels represents the mean relative transcript abundance (in log2 space); highest expression is red, average expression is black, and
lowest expression is green. Data represent the average of three independent experiments. (b) Detection of self-renewal transcription factors
OCT4, NANOG, SOX2, and ZIC1 expression by quantitative real-time polymerase chain reaction (qRT-PCR). Control cell lines used for gene
expression analyses include human dermal fibroblasts and human embryonic stem cells (hESCs). The mRNA levels were normalized to those of
the parental cell lines (p86 and p48). Bar graph represents the mean ± standard deviation (SD) of three independent experiments. (c) Detection
of tumor suppressor gene expression by qRT-PCR. Genes analyzed include p21WAF1/cip1, Dickkopf-related protein 1 (DKK1), methylguanine-DNA
methyltransferase (MGMT), Maspin (SERPINB5), and E-cadherin (CDH1). The mRNA levels were normalized to those of the parental cell lines (p86
and p48). Bar graph represents the mean ± SD of three independent experiments. NOS, NANOG, OCT4, and SOX2 targets.
Beltran et al. Breast Cancer Research 2011, 13:R94
http://breast-cancer-research.com/content/13/5/R94
Page 13 of 21
Interestingly, NOS targets are found over-represented
in poorly differentiated breast cancers and gliomas [13].
As expected, our microarray analysis has shown that
OCT4 mRNA was particularly enriched in the claudin-
low and basal-like intrinsic subtype of breast cancers
and also shows some expression in normal-like cancers
(Figure S3 in Additional file 9). Consistently, NOS tar-
gets are also over-represented in the same subtypes (Fig-
ure S4 in Additional file 10).
Upregulation of self-renewal transcription factors
NOS targets differentially upregulated in OTBCs relative
to the parental lines comprised multiple self-renewal
TFs. Of particular interest were OCT4, SOX2, NANOG,
and the EMT TFs ZEB1 and ZEB2, which are transcrip-
tional repressors of E-cadherin. Importantly, the endo-
genous levels of expression of OCT4 in OTBCs were
comparable to or even higher than those detected in
hESCs grown in self-renewal conditions. However,
SOX2 levels in OTBCs were lower than those observed
in hESCs. The downstream embryonic target of OCT4
NANOG, which is known to block differentiation gene
programs in hESCs, was found partially reactivated in all
of the OTBCs. In addition, we found that the NOS tar-
get gene ZIC1 was differentially regulated in all of the
OTBC lines (Figure 7b). ZIC1 is a zinc finger TF
expressed in hESCs [32] and has been shown to be
necessary for the maintenance of the self-renewal phe-
notype in neural progenitors [34]. Furthermore, our
upregulated gene signature (n = 534 genes) was
enriched in TFs, particularly embryonic targets of OCT4
that specify pattern formation, such as homeobox-con-
taining proteins (for example, the SIX1 TF) (Table S4 in
Additional file 7). Whereas homeobox TFs specifying
differentiation gene programs are repressed in hESCs,
these targets were found upregulated in OTBCs. Thus,
our analysis indicated that embryonic TF targets of
OCT4 are upregulated in OTBCs. Importantly, we
found that OCT4 targets exhibited different expression
patterns in OTBCs relative to hESCs.
Downregulation of tumor suppressor genes
NOS targets differentially downregulated in OTBCs rela-
tive to the parental lines comprised tumor suppressor
genes, including DKK1, an antagonist of the Wnt signal-
ing pathway. DKK1 is an NOS target abundantly
expressed in hESCs [32]. In contrast, we found that
DKK1 was downregulated in all OTBC lines. Indeed,
DKK1 has been shown to be a secreted tumor suppres-
sor in multiple breast cancer cell lines [35,36] and is
epigenetically silenced in some breast cancer cell lines
and primary tumors [37]. Similarly, multiple tumor sup-
pressor genes known to be methylated in breast cancer,
such as Maspin [38], CDH1 [39], MGMT [40], and
p21WAF1/Cip1 [41], were downregulated in OTBCs rela-
tive to the parental lines (Figure 8c).
We next investigated whether epigenetic mechanisms
could account for the silencing of tumor suppressors in
OTBCs. Tumor suppressor gene reactivation was exam-
ined in OTBCs treated with the methyltransferase inhi-
bitor 5-aza-2’-deoxycytidine (5-aza-2’dC) or the histone
deacetylase inhibitors (HDACis) suberoylanilide hydro-
xamic acid and trichostatin-A. As shown in Figure S5 in
Additional file 11, Maspin and CDH1 were both reacti-
vated upon treatment with 5-aza-2’dC as well as HDA-
Cis, whereas DKK1 and MGMT were significantly
reactivated upon treatment with HDACis only. These
results suggested that epigenetic silencing mechanisms
involving histone methylation and de-acetylation could
be responsible for the inactivation of a variety of tumor
suppressors in OTBCs.
RNA interference-mediated knockdown of self-renewal
NOS targets in OCT4-transduced breast cells
The role of OCT4 and potential oncogenic targets of
OCT4 in mediating the self-renewal phenotype in
OTBCs was investigated by loss-of-function experi-
ments. OTBCs were transfected with siRNAs specific for
OCT4 and the OCT4 targets NANOG and ZIC1 (Figure
8). siRNA-transfected cells were allowed to form spher-
oids in a tumorsphere formation assay. The viability of
the resulting tumorspheres was monitored by a Cell
Titer Glo (CTG) assay, which measures cell viability by
the release of ATP as a luminescent signal. As expected,
the knockdown of OCT4 had the strongest effect in
reducing the ability of OTBCs to form spheroids (Figure
8a). This drastic downregulation of cell viability pro-
moted by OCT4 knockdown was observed only in
OTBCs; no effect was seen in immortalized mammary
epithelial cells, which do not express OCT4 (Figure 8b).
This experiment demonstrates the pivotal role of OCT4
in maintaining the self-renewal characteristics of these
cells. Likewise, siRNA-mediated knockdown of NANOG
and ZIC1 significantly suppressed spheroid formation
(Figure 8a-c). Collectively, our data suggest that OTBCs
could be used as a claudin-low breast cancer model to
potentially identify novel therapeutic targets.
A putative model summarizing the above molecular
events is integrated in Figure 9. Our data suggest that
a rare subpopulation of cells (approximately 0.01% to
0.1%) within the human mammary epithelial cell popu-
lation is a target of OCT4. Overexpression of OCT4
cDNA resulted in a subpopulation of cells that acti-
vated self-renewal gene programs. These cells gener-
ated mesenchymal-appearing colonies on feeder
cultures and could be propagated in feeder-free (mam-
mosphere) conditions. Serial expansion of spheroids in
multiple (more than seven passages) mediated the
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progressive selection for TIC-like cells (Figure 9a). At
the molecular level, we propose that OTBCs gained
and sustained self-renewal by activation of a TF net-
work involving the embryonic targets of OCT4, such
as NANOG, ZIC1, and EMT TFs (Figure 9b). Activa-
tion of EMT TFs was accompanied by the suppression
of miRNAs involved in epithelial differentiation. Con-
comitantly with this activation of potential oncogenic
TFs, tumor suppressor gene panels were found down-
regulated in OTBCs. A compromised tumor suppressor
repertoire could result in the subsequent selection of
clones possessing tumorigenic ability.
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Discussion
The isolation and characterization of TICs from human
tumors and cell lines have been limited because these
cells represent a rare population of cells within the
tumor and also because of our lack of understanding of
their molecular signatures. In this paper, we have
described the isolation of TIC-like cells by exogenous
expression of the OCT4 TF in primary breast cell
preparations. We have also shown that OTBCs exhibit
an overlapping gene signature with claudin-low
carcinomas.
The relatively low (0.1% to 0.01%) frequency of
mesenchymal colonies in the transduced samples sug-
gests that a subpopulation of cells is the target of
OCT4. It is possible that, in addition to inducing an
expansion of a relatively undifferentiated and rare
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subpopulation of cells in the mammary gland (possibly a
self-renewal stem or an early progenitor cell or both),
OCT4 induces global epigenetic reprogramming in an
epithelial target cell type of the breast. It is well docu-
mented that OCT4 is an essential reprogramming factor
[42] and is sufficient to reprogram neural stem cells
toward an induced pluripotent state [43]. In epithelial
and other tissues, it is generally accepted that stem/pro-
genitor cells reprogram at a higher frequency than more
differentiated somatic cells, and this also suggests that
the target cells mediating the OCT4 phenotype are not
fully differentiated. However, to study whether OCT4
induces genome-wide epigenetic remodeling, global
changes in DNA and histone methylation need to be
evaluated in OTBCs.
To confirm the epithelial origin of OTBCs, we evalu-
ated their differentiation potential by placing the OTBCs
in differentiation conditions and performing a detection
of specific CKs, which are a hallmark of epithelial cells.
In 3D culture conditions, OTBCs formed TDLUs, which
were morphologically very similar to those reported for
breast stem and cancer stem cells [24]. When OTBCs
were placed in 2D cultures, small populations of cells
stained positive for myoepithelial markers (CK14, SMA,
and Maspin) or luminal CKs (CK19) or both. These
experiments demonstrated that OTBCs had an epithelial
origin, and the cell target of OCT4 was possibly a primi-
tive stem/progenitor cell. In self-renewal conditions,
OTBCs exhibited antigenic signatures characteristic of
prospective stem cells of the breast, such as low levels
of CD133, high CD49f, and an absence of EpCAM
expression. Given the current understanding of prospec-
tive signatures in the mammary gland hierarchy [8],
these antigenic signatures are consistent with a putative
breast stem/early progenitor cell identity. The finding
that all OTBCs analyzed were EpCAM- suggested that
OTBCs do not originate from prospective luminal-
restricted progenitor cells, which are presumably
EpCAM+. However, it is also possible that OTBCs origi-
nate from myoepithelial CD10+ restricted progenitors.
In addition to being enriched in prospective stem cell
signatures, OTBCs were enriched in the tumorigenic,
cancer stem cell CD44+/CD24- signature. Consistently,
we found that as few as 50 cells derived from our
OTBC lines was sufficient to generate tumors with
metastatic colonization abilities in nude mice.
Histopathological analysis of the tumors in nude mice
confirmed the epithelial origin of OTBCs. All OTBCs
analyzed generated poorly differentiated carcinomas of
the breast and revealed an epithelial morphology with a
relatively high nuclear-to-cytoplasmic ratio and brisk
mitotic activity. These tumors were negative for ER, PR,
and HER2 and were positive for both OCT4 and the
mesenchymal marker VIM. Examination of CK staining
also revealed that a subset of tumor cells was immunor-
eactive for CK/pan-keratin, which further supports their
classification as a poorly differentiated carcinoma.
To gain a mechanistic understanding of how OCT4
immortalized and transformed the target cells, we per-
formed gene expression microarray experiments. The
comparison of genome-wide transcriptional profiles of
OTBCs with their parental lines revealed a gene signa-
ture that was over-represented in the newly discovered
claudin-low intrinsic subtype of breast cancer. Claudin-
low carcinomas were recently identified by Herschko-
witz and colleagues [44] and further characterized by
using a large database of human breast tumors [6,44]
and cell lines [6]. Although claudin-low tumors are rela-
tively rare (representing up to 11% of all breast cancers),
they are associated with poor patient survival [6,10].
Claudin-low carcinomas uniquely express low levels of
tight and adherent junction genes, including claudins
and E-cadherin [6,12]. Hallmarks of these tumors
include enrichment in EMT markers (VIM and Twist)
and putative TIC markers (CD44+/CD24- ratios) [10].
Recent genome-wide analysis suggests that this newly
discovered intrinsic subtype of breast cancer is closely
related to putative EpCAM- mammary stem cells [8,9].
Basal-like breast cancer, which is associated with muta-
tions in the tumor suppressor gene BRCA1, appears to
be more closely related to an EpCAM+ luminal-
restricted progenitor cell population [8]. Further support
for the hypothesis that claudin-low carcinomas may
arise from primitive stem/progenitor cells is provided by
clinical data, which show that TICs are enriched in
patients with breast cancer after neo-adjuvant therapy
[45]. Recent gene expression microarray analyses of
these TICs revealed enrichment in EMT gene signatures
[11]. Similarly, OTBCs exhibited enrichment in
mesenchymal markers and TIC features. Compared with
their parental lines, OTBCs upregulated the EMT TFs
SNAIL, TWIST, and ZEB1/2 as well as microRNAs asso-
ciated with EMT, such as miR-200s family members and
miR-205. EMT has been associated with stemness. The
forced expression of EMT TFs in immortalized breast
epithelial cells led to stem cell-like characteristics and
induction of TIC surface antigens [12].
Recently, ectopic expression of OCT4 and NANOG
was shown to enhance malignancy and induce EMT in
lung adenocarcinoma cell lines [46]. This finding con-
firms our results that link OCT4 and NANOG as poten-
tial oncogenes, which drive EMT processes in the
mammary tissue. OCT4 expression was recently demon-
strated in the MMTV-Wnt1 mouse models of breast
cancer [47]. Recent work on epithelial ovarian cancer
has shown that pluripotency TFs, such as OCT4 and
NANOG, are overexpressed in poorly differentiated
epithelial ovarian cancers. Furthermore, the RNAi
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knockdown of OCT4 in these cells prevented or blocked
their ability to generate spheroids [16,48]. Likewise, a
similar report in the MCF-7 breast cancer cell line
demonstrated that the knockdown of OCT4 induced
tumor cell death [17]. Our loss-of-function studies also
outlined the crucial role of OCT4 and its downstream
targets in maintaining self-renewal and EMT in our
OTBC lines. We found that the hESC NOS target ZIC1
was upregulated in all OTBCs. Recent reports have sug-
gested that ZIC1 is overexpressed in brain [49] and lung
[50] tumors. Analysis of transcriptional profiles of large
cohorts of human tumors revealed that ZIC1 mRNA is
overexpressed in poorly differentiated carcinomas,
including breast cancers [13]. We found that siRNA-
mediated knockdown of ZIC1 suppressed the ability of
OTBCs to form spheroids in vitro, outlining an impor-
tant role of ZIC1 as a potential oncogene in claudin-low
carcinomas. These data suggest that OTBCs can be used
as model systems to identify oncogenic targets in clau-
din-low carcinomas.
In hESCs, OCT4 acts as a gatekeeper of self-renewal
and master regulator of a TF network [33,51]. Indeed,
knockdown of OCT4 in hESCs or epigenetic silencing
of its promoter irreversibly blocks self-renewal and plur-
ipotency and triggers differentiation gene programs.
Consistent with the ability of OTBCs to maintain self-
renewal, we found that these lines also activated the
endogenous hESC TF network. We speculate that over-
expression of OCT4 in a subpopulation of cells in the
mammary gland was able to maintain these cells in a
‘locked in’ and undifferentiated state, limiting them from
undergoing downstream lineage specification gene pro-
grams. This explanation is consistent with a mouse
model of OCT4 cDNA overexpression, which demon-
strates that OCT4 generates hyperplasia of the skin and
colon by possibly targeting progenitor cells [15].
Although the exact mechanism by which OCT4 trig-
gers the TIC-like phenotype needs further investigation,
we speculate that gain of self-renewal ability is a com-
plex genome-wide phenomenon that requires endogen-
ous reactivation of a TIC self-renewal TF network. This
model is consistent with our microarray data, which
show that direct targets of NANOG, OCT4, and SOX2
(NOS targets), which are reasonably well characterized
in hESCs, are also differentially regulated in OTBCs
relative to their parental lines. Thus, OTBCs could
mimic or even corrupt a basic hESC self-renewal TF
network, which involves protein-protein associations
acting in a combinatorial manner at specific promoter
sites [50-54]. The characterization of this TIC-like TF
network and specifically how this protein network dif-
fers from hESCs will require further study. In a TIC,
this network may similarly involve associations between
TFs, such as OCT4 and NANOG, and co-activator or
co-repressor complexes as well as chromatin remode-
lers. This combinatorial occupancy of factors at specific
promoters could result in the activation of potential
oncogenes and self-renewal gene programs as well as
the repression of selected tumor suppressor genes.
Importantly, our data suggest that NOS targets are
regulated differently in TICs relative to hESCs. DKK1,
an antagonist of the Wnt signaling pathway, is abun-
dantly expressed in hESCs. In contrast, this target was
found downregulated in OTBCs. Indeed, DKK1 is a
secreted tumor suppressor in breast cancer [35,36]. Wnt
signaling in breast cancer has been linked to EMT
through stabilization of Snail [55] and upregulation of
the EMT TFs SLUG and TWIST [56,57]. Overexpres-
sion of DKK1 in a breast cancer cell line resulted in an
inhibition of self-renewal ability. Thus, downregulation
of the NOS target DKK1 in OTBCs is consistent with
gain of self-renewal ability and mesenchymal character-
istics via the upregulation of EMT TFs.
In hESCs, OCT4 represses TFs involved in pattern
specification, such as homeobox-containing proteins. In
contrast, homeobox-containing TFs were highly
enriched in our OTBC upregulated gene signature. The
homeobox TF SIX1 was found upregulated in the
OTBCs relative to parental lines. Overexpression of
SIX1 in the mouse mammary gland promoted an expan-
sion of stem/progenitor cells and subsequent tumor
development [58]. In a parallel study, Micalizzi and col-
leagues [59] reported that overexpression of SIX1 also
facilitated breast cancer metastasis by induction of EMT.
In conclusion, our data support a mechanism by
which differential regulation of downstream targets of
OCT4 led to activation of oncogenes and downregula-
tion of tumor suppressors. Since OTBCs sustained aber-
rant self-renewal, it is possible that these cells gained
TIC features by selective amplification of spheroids. A
compromised tumor suppressor repertoire could result
in subsequent selection of clones possessing tumorigenic
ability. The molecular events leading to upregulation of
TF genes and downregulation of multiple tumor sup-
pressor genes are unknown at present; however, genetic
and epigenetic events might be involved. In hESCs, acti-
vation of TF networks is associated with promoter de-
methylation and gene reactivation. Loss of tumor sup-
pressor functions in OTBCs could also involve genetic
and epigenetic silencing mechanisms. Downstream epi-
genetic regulators of OCT4, such as DNMT3a/b, could
be involved in this concerted silencing of tumor sup-
pressor genes [60]. Alternatively, OCT4 and other self-
renewal TFs could be associated with large silencing
complexes involving HDACs, such as NODE [61] and
NuRD [62], which have been well described in hESCs.
Consistent with the idea of epigenetic modulation trig-
gered by OCT4, we found that methyltransferase
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inhibitors and HDACis were able to partially reactivate
tumor suppressor genes in OTBCs. In summary, our
data describe the generation of novel claudin-low cell
lines that could be used by breast cancer investigators
to analyze genetic and epigenetic determinants of tumor
initiation.
Conclusions
In this article, we have shown that overexpression of
OCT4 cDNA into normal primary breast epithelial pre-
parations generated clonal populations of cells with
aberrant self-renewal that developed tumor initiation
ability. When injected in nude mice, these cells devel-
oped poorly differentiated, mesenchymal-enriched, and
triple-negative breast carcinomas. OCT4-transduced
breast colonies exhibited genome-wide signatures that
are over-represented in the claudin-low intrinsic subtype
of breast cancer. Our data suggest that OCT4 expands
an early stem/progenitor cell and activates an embryo-
nic-like TF network. Using siRNAs, we have validated
the role of OCT4 and embryonic targets of OCT4, such
as NANOG and ZIC1, in mediating the self-renewal
phenotype. Our experimental approach provides a novel
model system that can be used to identify therapeutic
targets involved in breast cancer self-renewal and tumor
initiation in a patient-specific manner.
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